Cat. No.: HY-W011927

4,4'-Sulfonyldiphenol

(Synonyms: Bisphenol S; Bis(4-hydroxyphenyl) sulfone)

Avis client

Based on 1 Customer Validation

4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone), a substitute for Bisphenol A (HY-18260), is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC₅₀ values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.44%
CAS No.: 80-09-1
Formule: C₁₂H₁₀O₄S
Masse moléculaire:250.28

Stockage:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

4,4'-Sulfonyldiphenol Chemical Structure

CAS No.: 80-09-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Estrogen Receptor/ERR :

Voir tous les produits spécifiques à Isoform Histone Methyltransferase :

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform mTOR :

In Vitro

4,4'-Sulfonyldiphenol (0-50 μM) induces thyroid hormone (TH)-dependent GH3 cell proliferation, and inhibits T3 (HY-A0070A) induction in the presence of T3^[3].
4,4'-Sulfonyldiphenol (100 μM, 24 h) Significantly increases lipid deposition in AML12 and primary hepatocytes via the JunB/ATF3 axis^[4].
4,4'-Sulfonyldiphenol (0.001-100 μM, 4-24 h) promotes the proliferation and migration of U-87 MG cells at a concentration of 0.1 µM and appears to be linked to the activation of the EZH2-mediated PI3K/ AKT/mTOR pathway^[6].
4,4'-Sulfonyldiphenol (0.01-1 μM, 0-24 h) exhibits enhanced formation of foam cells with oxidized lowdensity lipoprotein (oxLDL) in macrophages^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[6]

Cell Line:

U-87 MG cells
Concentration:

0, 0.001, 0.01, 0.1, 1, 10 and 100 μM
Incubation Time:

4 and 8 h
Result:

Significantly increased the proliferation rate at 0.1 μM, and the effect was more significant after 8 hours of treatment than after 4 hours.

Cell Migration Assay ^[6]

Cell Line:

U-87 MG cells
Concentration:

0.1 μM
Incubation Time:

0, 2, 4, 6, 8, 10 and 12 h
Result:

Significantly increased the mobility within 12 hours.

Cell Invasion Assay^[6]

Cell Line:

U-87 MG cells
Concentration:

0.1, 1 and 10 μM
Incubation Time:

24 h
Result:

Induced glioblastoma invasion in U-87 MG cells.

RT-PCR^[6]

Cell Line:

U-87 MG cells
Concentration:

0.1 μM
Incubation Time:

4 and 8 h
Result:

Increased the mRNA level of EZH2.

Western Blot Analysis^[6]

Cell Line:

U-87 MG cells
Concentration:

0.1 μM
Incubation Time:

4 and 8 h
Result:

Increased the expression of EZH2, p-PI3K, p-AKT, p-mTOR and p-4E-BP1.
Decreased the expression of PIK3IP1.

In Vivo

4,4'-Sulfonyldiphenol (2-2000 μg/kg, p.o., starting on pregnancy day 9 through lactation day 2 or 20 ) alters the growth of the mammary epithelium and sensitizes males to additional estrogen exposures encountered at puberty in mice^[1].
4,4'-Sulfonyldiphenol (0.2-50 μg/kg, p.o., once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old) can be an obesogen at low doses and after perinatal and chronic exposure for the male mice^[2].
4,4'-Sulfonyldiphenol (0-10 μM, single dose) induces TH-response gene transcription in Pelophylax nigromaculatus tadpoles, but in the presence of T3 altered T3-induced gene transcription in a biphasic concentration-response manner^[3].
4,4'-Sulfonyldiphenol (0.1-1 mg/kg, i.g., once daily for 3 months) induces mice to show signiﬁcant lipid deposition in the liver and dyslipidemia and were predisposed to metabolic dysfunction-associated steatotic liver disease (MASLD)^[4].
4,4'-Sulfonyldiphenol (0.1-1 mg/kg, i.g., once daily for 3 months) induces intestinal inflammation via altering gut microbiome in mice^[5].
4,4'-Sulfonyldiphenol (0-100 μg/L, for 15-45 days) accelerates the progression of atherosclerotic cardiovascular disease (ASCVD) using zebrafish embryo-larvae as a model^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Long-term and short-term exposure effect assessment established in female CD-1 mice^[1]
Dosage:

2 and 200 μg/kg (long-term); 2, 200, and 2000 μg/kg (short-term)
Administration:

Oral administration (p.o.), once daily starting on pregnancy day 9 through lactation day 20 (long-term) and starting on pregnancy day 9 through lactation day 2 (short-term)
Result:

Showed signs of ductal formation in the mammary gland and significantly enlarged the intercellular spaces between the tissues.
Increased ERα expression in epithelial cells and dose-dependently decreased AR expression in the stroma.
Increased the right duct area in all groups, and the left duct area also increased significantly in the high-dose group.
Altered the response of male mice to a pre-pubertal estrogen challenge.

Animal Model:

High fat diet model established in pregnant C57Bl/6J mice^[2]
Dosage:

0.2, 1.5, 50 µg/kg
Administration:

Oral administration (p.o.) with water, once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old
Result:

Significantly increased in body weight and fat mass on a high-fat diet.
Had no effect on the food intake and energy expenditure.
Exhibited a weak but significant hypercholesterolemia with a fold increase of 1.21 and 1.29 at 1.5 and 50 µg/kg, respectively.
Showed a significant decrease of the AUC (increase of blood TG clearance).
Significantly increased the calculated HOMA-IR index in mice exposed to 1.5 and 50 µg/kg.
Induced a significant overexpression of SOCS3 mRNA and a significant mRNA down-regulation of INSR and adiponectin.
Induced a weak but significant decrease in mRNA expression of HSL and PPARγ genes in adipose tissue of male mice fed with a HFD.

Animal Model:

MASLD model established in 7-week-old C57BL/6 male mice^[4]
Dosage:

0.1 and 1 mg/kg
Administration:

Oral gavage (i.g.), once daily for 3 months
Result:

Induced MASLD phenotype: elevated LDL, increased NEFA, and elevated ALT.
Showed obvious lipid droplet accumulation.

Animal Model:

Intestinal inflammation model established in 6-7 week old male C57BL/6 mice^[5]
Dosage:

0.1 and 1 mg/kg alone and 1 mg/kg with antibiotic cocktail (ABX)
Administration:

Oral gavage (i.g.), once daily for 3 months alone and also for 3 months, during the exposure process, every two-week ABX treatment was followed by a two-week recovery in cycles
Result:

Led to typical features of intestinal inflammation: significant shortening of colon length, tissue pathological damage, increased immune cell infiltration and apoptosis.
Induced bacterial imbalance, increasing pro-inflammatory bacteria and decreasing anti-inflammatory bacteria.
Caused an increase in arachidonic acid (pro-inflammatory) and a decrease in madecainic acid (anti-inflammatory).
Normalized intestinal inflammation, improved metabolism after antibiotic intervention.

Chemical Information

CAS No. 80-09-1
Appearance Solid
Masse moléculaire 250.28
Formule C₁₂H₁₀O₄S
Color White to yellow
SMILES

O=S(C1=CC=C(O)C=C1)(C2=CC=C(O)C=C2)=O
Synonyms

Bisphenol S; Bis(4-hydroxyphenyl) sulfone
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (399.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9955 mL

19.9776 mL

39.9552 mL

5 mM

0.7991 mL

3.9955 mL

7.9911 mL

10 mM

0.3996 mL

1.9978 mL

3.9955 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kolla S, et al. Bisphenol S alters development of the male mouse mammary gland and sensitizes it to a peripubertal estrogen challenge. Toxicology. 2019 Aug 1;424:152234. [Content Brief]

[2]. Ivry Del Moral L, et al. Obesogen effects after perinatal exposure of 4,4'-sulfonyldiphenol (Bisphenol S) in C57BL/6 mice. Toxicology. 2016 May 16;357-358:11-20. [Content Brief]

[3]. Zhang YF, et al. Bisphenol A alternatives bisphenol S and bisphenol F interfere with thyroid hormone signaling pathway in vitro and in vivo. Environ Pollut. 2018 Jun;237:1072-1079. [Content Brief]

[4]. Li S, et al. Bisphenol S Exposure and MASLD: A Mechanistic Study in Mice. Environ Health Perspect. 2025 May;133(5):57009. [Content Brief]

[5]. Ko MY, et al. Bisphenol S (BPS) induces glioblastoma progression via regulation of EZH2-mediated PI3K/AKT/mTOR pathway in U87-MG cells. Toxicology. 2024 Sep;507:153898. [Content Brief]

[6]. Wang W, et al. Bisphenol S exposure accelerates the progression of atherosclerosis in zebrafish embryo-larvae. J Hazard Mater. 2022 Mar 15;426:128042. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9955 mL	19.9776 mL	39.9553 mL	99.8881 mL
	5 mM	0.7991 mL	3.9955 mL	7.9911 mL	19.9776 mL
	10 mM	0.3996 mL	1.9978 mL	3.9955 mL	9.9888 mL
	15 mM	0.2664 mL	1.3318 mL	2.6637 mL	6.6592 mL
	20 mM	0.1998 mL	0.9989 mL	1.9978 mL	4.9944 mL
	25 mM	0.1598 mL	0.7991 mL	1.5982 mL	3.9955 mL
	30 mM	0.1332 mL	0.6659 mL	1.3318 mL	3.3296 mL
	40 mM	0.0999 mL	0.4994 mL	0.9989 mL	2.4972 mL
	50 mM	0.0799 mL	0.3996 mL	0.7991 mL	1.9978 mL
	60 mM	0.0666 mL	0.3330 mL	0.6659 mL	1.6648 mL
	80 mM	0.0499 mL	0.2497 mL	0.4994 mL	1.2486 mL
	100 mM	0.0400 mL	0.1998 mL	0.3996 mL	0.9989 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

4,4'-Sulfonyldiphenol

Bioactive Compound Library Max

Bioactive Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Voir tous les produits spécifiques à Isoform Estrogen Receptor/ERR

Voir tous les produits spécifiques à Isoform Histone Methyltransferase

Voir tous les produits spécifiques à Isoform PI3K

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform mTOR

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

4,4'-Sulfonyldiphenol Related Classifications

HY-W011927 Related Classifications